Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940895 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
A Phase 2 study, sponsored by Narrows Institute for Biomedical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06940895 is a Phase 2 study that has completed, run by Narrows Institute for Biomedical Research. The registered enrollment target is 5 participants.
The verdict
NCT06940895, a Phase 2 study, has completed, sponsored by Narrows Institute for Biomedical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Interventions
- DRUG Sirolimus 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940895
The ClinicalTrials.gov registry entry for NCT06940895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Narrows Institute for Biomedical Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus 0.2% is the first listed.
NCT06940895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06940895 about?
NCT06940895 is a clinical study titled "Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans". The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
What is the current status of trial NCT06940895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-03-01. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT06940895?
The interventions under investigation include: Sirolimus 0.2% (DRUG).
Who is sponsoring clinical trial NCT06940895?
This trial is sponsored by Narrows Institute for Biomedical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.